| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/24/2008 | US7390630 Method of identifying a compound that selectively inhibits cytokine-stimulated T cell induced production of TNF-alpha by monocytes |
| 06/24/2008 | US7390625 Apoptosis-associated protein and use thereof |
| 06/24/2008 | US7390519 Probiotic Lactobacillus salivarius strains |
| 06/24/2008 | US7390505 Nanoparticulate topiramate formulations |
| 06/24/2008 | US7390500 Transdermal therapeutic system (TTS) with fentanyl as a active ingredient |
| 06/24/2008 | US7390484 Self-contained adipose derived stem cell processing unit |
| 06/19/2008 | WO2008074033A1 Compositions and methods of using (r)-pramipexole |
| 06/19/2008 | WO2008073958A2 Substituted benzothiadiazinedioxide derivatives and methods of their use |
| 06/19/2008 | WO2008073943A1 Dihydrobenzofuranyl derivatives and methods of their use |
| 06/19/2008 | WO2008073942A2 Pharmaceutical compositions and their methods of use |
| 06/19/2008 | WO2008073789A1 Ampa receptor potentiators |
| 06/19/2008 | WO2008073779A2 Compositions and methods for treating seizures |
| 06/19/2008 | WO2008073466A2 Alpha b-crystallin as a therapy for inflammation |
| 06/19/2008 | WO2008073461A2 Ion channel modulators |
| 06/19/2008 | WO2008073395A2 Compositions and methods for cardiac tissue protection and regeneration |
| 06/19/2008 | WO2008073365A1 Aspartyl protease inhibitors |
| 06/19/2008 | WO2008072779A1 Quinoxaline derivative |
| 06/19/2008 | WO2008072726A1 1-phenyl 1-thio-d-glucitol derivative |
| 06/19/2008 | WO2008072724A1 Pyrazole derivative |
| 06/19/2008 | WO2008072703A1 Biphenylamide derivative |
| 06/19/2008 | WO2008071991A1 Treatment of pervasive developmental disorders |
| 06/19/2008 | WO2008071960A2 Methods of increasing neurogenesis |
| 06/19/2008 | WO2008071779A1 V3 antagonists for the treatment or prevention of chronic pain |
| 06/19/2008 | WO2008071755A2 Casein-derived peptides having anxiolytic activity |
| 06/19/2008 | WO2008071738A1 Selective inhibitors of neurotensin degrading enzymes |
| 06/19/2008 | WO2008071736A1 Benzamide derivatives as ep4 receptor agonists |
| 06/19/2008 | WO2008071665A1 A nicotinamide derivative useful as p38 kinase inhibitor |
| 06/19/2008 | WO2008071664A1 Nicotinamide derivative used as a p38 kinase inhibitor |
| 06/19/2008 | WO2008071605A2 Methods of treating inflammatory diseases |
| 06/19/2008 | WO2008071574A1 Novel 2 -imidazoles as ligands for trace amine associated receptors (taar) |
| 06/19/2008 | WO2008071438A2 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor |
| 06/19/2008 | WO2008070994A1 Use of d-serine derivatives for the treatment of anxiety disorders |
| 06/19/2008 | WO2008055022A3 Carbamate compounds for use in treating depression |
| 06/19/2008 | WO2008052078A3 Benzoxathiine and benzoxathiole derivatives and uses thereof |
| 06/19/2008 | WO2008052075A3 Benzoxazine derivatives and uses thereof |
| 06/19/2008 | WO2008049996A3 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 06/19/2008 | WO2008049058A3 Cln2 treatment of alzheimer's disease |
| 06/19/2008 | WO2008045371A3 N-substituted-azacyclylamines as histamine-3 antagonists |
| 06/19/2008 | WO2008041134A3 Use of chlorine guanabenz derivatives for treating prion-based diseases |
| 06/19/2008 | WO2008036400A3 Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome |
| 06/19/2008 | WO2008034202A3 Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis |
| 06/19/2008 | WO2007127474A3 Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| 06/19/2008 | WO2007045060A8 Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production |
| 06/19/2008 | US20080146836 New Aminopropylphosphinic acids |
| 06/19/2008 | US20080146810 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 06/19/2008 | US20080146660 Androgen receptor antagonists; certain cancers such as colon, skin and prostate cancer, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired |
| 06/19/2008 | US20080146647 Acetylene derivatives having mglur 5 antagonistic activity |
| 06/19/2008 | US20080146642 Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease |
| 06/19/2008 | US20080146635 Selective to alpha2B and/or alpha2C adrenergic receptors, minimal cardivascular and/or sedatory activity; treating pain, visceral pain, neuropathic pain, corneal pain, glaucoma, elevated intraocular pressure, ischemic neuropathies, neurodegenerative diseases, diarrhea, nasal congestion |
| 06/19/2008 | US20080146630 Estrogen receptor modulators; neurodegenerative disorders; cognitive enhancement |
| 06/19/2008 | US20080146627 Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. |
| 06/19/2008 | US20080146622 E.g., rotigotine; have neuroprotective properties and can be used for treatment or prophylaxis of dopaminergic cell loss, particularly in very early stages of Parkinson's disease or in high-risk patients |
| 06/19/2008 | US20080146621 N-{[1-(Methylamino)cyclopropyl]methyl}pyridin-3-amine dihydrochloride; treatment of neuropathologies associated with cerebral ageing, of mood disorders, of pain and of tobacco withdrawal; selective nicotinic ligands of the central receptor sub-type alpha 4 beta 2 |
| 06/19/2008 | US20080146614 Therapeutic Agents |
| 06/19/2008 | US20080146611 Transient Receptor Potential channel modulators; N-(2-pyridinyloxy- or 2-pyridinylthio-alkanoyl)quinolines; acute or chronic pain, sensitivity, burns, diabetic neuropathy, psoriasis, eczema, dermatitis, post-herpetic neuralgia, migraine, incontinence, fever, hot flashes, osteoarthritis; depilatories |
| 06/19/2008 | US20080146607 heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents |
| 06/19/2008 | US20080146604 adenosine receptor antagonists such as 2-(4-Methoxyphenyl)-9-benzylamino-10-cyano-s-triazolo[1,5-a]quinolin, used for treating respiratory system disorders, vision disorders, tumors, allergies or inflammatory disease, ischemia, hypoxia, arrhythmia or urogential disorders |
| 06/19/2008 | US20080146601 Method for making analgesics |
| 06/19/2008 | US20080146600 potent proline transporter inhibitors such as (S)-2-(4-((3'-chlorobiphenyl-4-yl)(hydroxy)methyl)piperidin-1-yl)pyrimidin-5-ol, used as cognition activators or for treatment of brain disorders |
| 06/19/2008 | US20080146596 Such as (R)-2-(4-((3'-chlorobiphenyl-4-yl)(hydroxy)methyl)piperidin-1-yl)pyrimidin-5-ol for treating age-associated memory impairment, Alzheimer's disease, attention-deficit/hyperactivity disorder, autism, Down syndrome, Fragile X syndrome, Huntington's disease, Parkinson's disease, or schizophrenia |
| 06/19/2008 | US20080146588 Piperidinyl Piperidine Tachykinin Receptor Antagonists |
| 06/19/2008 | US20080146587 for enhancing cognitive memory in an Alzheimer's patient; 5-HT2-selective and 5-HT6 selective ligands |
| 06/19/2008 | US20080146582 Diazabicyclic Aryl Derivatives and Their Use as Chinolinergic Ligands at the Nicotinic Acetylcholine Receptors |
| 06/19/2008 | US20080146577 Methods and Compositions for the Treatment of Attention Deficit Hyperactivity Disorder and Hyperphenylalanemia |
| 06/19/2008 | US20080146575 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis |
| 06/19/2008 | US20080146567 5-HT5A receptor antagonists; depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, drug withdrawal |
| 06/19/2008 | US20080146557 Vasopressin (V1a) receptor; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders; 1'-[(1-benzyl-2-methyl-1H-indol-3-yl)carbonyl]spiro[indene-1,4'-piperidine] one for example |
| 06/19/2008 | US20080146549 Administering sedative and microdose of opioid antagonist for at least one day followed by detoxifying amount of second antagonist prior to prolonged treatment with third antagonist; low cost; promotes abstinence |
| 06/19/2008 | US20080146546 Bicyclic and Tricyclic Heteroaromatic Compounds |
| 06/19/2008 | US20080146545 Macrocyclic compounds useful as inhibitors of kinases and HSP90 |
| 06/19/2008 | US20080146536 2-Aminoimidazopyridines for treating neurodegenerative diseases |
| 06/19/2008 | US20080146531 Therapeutically Active Triazoles and Their Use |
| 06/19/2008 | US20080146530 Re-epithelializing pharmaceutical compositions comprising xanthan gum |
| 06/19/2008 | US20080146526 e.g. 3-{[1-Isobutanoyloxyethoxy]carbonylamino}propyl(n-butyl)phosphinic acid; prodrugs of baclofen; gamma aminobutanoic acid antagonist; antidepressant, anxiolytic agent, cognition activator; Alzheimer's disease, epilepsy |
| 06/19/2008 | US20080146525 Composition for promoting cognitive attributes |
| 06/19/2008 | US20080146524 Such as 3-[Hydroxy-(3-phenyl-butyl)-phosphinoyl]-propionyl)-2-amino-(3-methyl-butyrylamino)hexcanoic acid; intermediates; potent and selective endopeptidases inhibitors |
| 06/19/2008 | US20080146508 Soluble cyclic analogues of beta amyloid peptide |
| 06/19/2008 | US20080146506 Methods of Suppressing Microglial Activation |
| 06/19/2008 | US20080146505 47 Human Secreted Proteins |
| 06/19/2008 | US20080146504 Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
| 06/19/2008 | US20080146491 treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the calcitonin, calcitonin-like peptides or calcitonin |
| 06/19/2008 | US20080145943 Cng2b: a novel human cyclic nucleotide-gated ion channel |
| 06/19/2008 | US20080145461 Formulation and method of making a topical pain relief composition |
| 06/19/2008 | US20080145460 Topical mixture of dimethicone, cyclomethicone; mineral oil; Aloe vera gel; a vitamin E, vitamin A |
| 06/19/2008 | US20080145453 4-(piperimidine-2thione)phenyl derivatives; kinesin Eg5 inhibitor; anticarcinogenic agent; the aldehyde, the ketone and the thiourea are reacted together in the solid phase, grafted onto resin by esterification, and detached by hydrolysis |
| 06/19/2008 | US20080145451 Composition for relieving discomfort |
| 06/19/2008 | US20080145449 Thiol reactive agents as a therapeutic modality |
| 06/19/2008 | US20080145429 Dosage Form Containing Oxycodone and Naloxone |
| 06/19/2008 | US20080145425 Pharmaceutical composition of zolpidem |
| 06/19/2008 | US20080145417 Pharmaceutical formulation for the efficient administration apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof |
| 06/19/2008 | US20080145365 Human and mammalian stem cell-derived neuron survival factors |
| 06/19/2008 | US20080145352 Method for promoting axonal re-growth and behavior recovery in spinal cord injury |
| 06/19/2008 | US20080145340 Neuroactive agents and methods of their use |
| 06/19/2008 | US20080145335 Which protect neural cells from degeneration and/or death in response to injury or disease; hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease |
| 06/19/2008 | US20080145314 EGFR inhibitors promote axon regeneration |
| 06/19/2008 | DE102007043613A1 Medicament, useful for the treatment of Alzheimer's disease, comprises a pure biological alcohol, which is obtained from plants, preferably berries, fruits, herbs or its derivatives |
| 06/19/2008 | DE102006058209A1 New triterpene type compounds comprising a pentacyclic basic unit of nor-oleanane- or nor-ursane-type, are 11-beta-hydroxysteroid dehydrogenase inhibitors, useful e.g. to treat and prevent diabetes, depression and glaucoma |
| 06/19/2008 | DE102006058207A1 New triterpene type compounds comprising a pentacyclic basic structure of nor-oleanan- or non-ursan -types are 11-beta-hydroxysteroid dehydrogenase inhibitors, useful e.g. to treat and prevent the diabetes, depression and glaucoma |
| 06/19/2008 | CA2707542A1 Casein-derived peptides having anxiolytic activity |
| 06/19/2008 | CA2672738A1 Treatment of pervasive developmental disorders |